Sonya Youngju Park

The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.

Purpose The aim of this study was to assess the value of dual–time point PET/CT in the differentiation of extrahepatic cholangiocarcinoma from benign stricture and the added benefits of delayed PET/CT image. Patients and Methods Thirty-nine patients with suspected extrahepatic biliary malignancy based on conventional imaging studies such as ultrasonography, CT, and MRI between July 2008 and December 2010 were included. All patients underwent dual–time point PET/CT scans at 1 and 2 hours after radiotracer injection. From the site of suspected malignancy, the SUVmax for both time points (SUVmax1 and SUVmax2), the percent change in SUVmax between the 2 (&Dgr;%SUVmax) and the ratio of SUVmax1, SUVmax2, &Dgr;%SUVmax in comparison with average SUV of right hepatic lobe (T/L ratio1, T/L ratio2, and &Dgr;%T/L ratio) were generated. Diagnostic performances using visual assessment and various SUVmax cutoff values were analyzed in the differential diagnosis of extrahepatic cholangiocarcinoma from benign disease. PET/CT results were correlated with histological results and radiological follow-up for at least 6 months. Results Of 39 patients, the final diagnosis was cholangiocarcinoma in 34 and benign disease in 5. Between malignant and benign lesions, there were significant differences in SUVmax1 (5.43 ± 4.66 vs 2.26 ± 0.83, P = 0.003) and SUVmax2 (6.02 ± 5.26 vs 2.26 ± 0.76, P = 0.002). There was no significant difference in &Dgr;%SUVmax, T/L ratio1, T/L ratio2, and &Dgr;%T/L ratio. On receiver operator curve analysis, SUVmax1 with cutoff value of 2.5 demonstrated sensitivity of 97.6%, specificity of 60.0%, and accuracy of 92.3% and SUVmax2 with cutoff value of 3.1 demonstrated sensitivity of 88.2%, specificity of 100%, and accuracy of 89.7%. Conclusion SUVmax from both early and delayed PET/CT scans are useful parameters in the differentiation of extrahepatic biliary malignancy from benign disease. However, there was no added benefit of delayed PET/CT in patients suspicious for extrahepatic cholangiocarcinoma.

The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI

Background Accurate assessment of neoadjuvant chemotherapy (NAC) response with positron emission tomography/computed tomography (PET/CT) or magnetic resonance imaging (MRI) may provide appropriate operation guidelines for individual breast cancer patients. Purpose To compare the values of PET/CT and MRI for response evaluation following NAC in breast cancer patients. Material and Methods Thirty-three consecutive patients who underwent NAC were included. PET/CT and MRI were performed before and one to four weeks after NAC. With response evaluation of PET/CT and MRI, patients with complete/partial responses on imaging studies were considered to be responders, and those showing stable/progressive disease non-responders. Peak standardized uptake value corrected for lean body mass (SULpeak) and metabolic tumor volume (MTV) were measured from PET/CT, and unidimensional diameter (1D) and tumor volume (TV) from MRI. Reduction rates for each parameter were calculated (Δ%SULpeak, Δ%MTV, Δ%1D, and Δ%TV). The pathological response for NAC as reference was evaluated after surgical resection of the remaining tumor in the breast. Results We identified 17 pathological responders and 16 non-responders. PET/CT had lower specificity and accuracy, but higher sensitivity than MRI, although no significant difference was found between PET/CT and MRI. Following NAC, there were significant differences between pathological responders and non-responders in SULpeak (P < 0.001), MTV (P < 0.001), 1D (P = 0.0003), TV (P = 0.038), Δ%SULpeak (P = 0.001), Δ%MTV (P < 0.001), Δ%1D (P < 0.001), and Δ%TV (P = 0.001). Conclusion PET/CT showed lower specificity and accuracy than MRI in evaluating responses to NAC, but both PET/CT and MRI parameters may have predictive value in distinguishing therapeutic responders and non-responders following NAC.

Significance of Incidental Nasopharyngeal Uptake on 18F-FDG PET/CT: Patterns of Benign/Physiologic Uptake and Differentiation from Malignancy

PurposeThe purpose of this study was to assess the significance of incidental nasopharyngeal uptake on 18F-FDG PET/CT and to identify image patterns useful in the differentiation between benign or physiologic activity and nasopharyngeal carcinoma.MethodsWe retrospectively reviewed medical records of patients with nasopharyngeal uptakes on 18F-FDG PET/CT scans taken between January 2010 and July 2011. Patients with head and neck cancer, other metastatic head and neck lesions, or lymphoma were excluded. Total 177 patients were enrolled (Group A). PET images were reviewed for patterns of nasopharyngeal FDG uptake, presence/absence of cervical lymph node uptake and pattern of cervical node uptake. Diagnostic confirmation was made by pathology or clinical and radiological follow-up for 1 year or longer. Furthermore, initial PET/CT images of 48 patients with nasopharyngeal carcinoma (Group B) were reviewed for comparison with PET/CT images of Group A patients.ResultsAll nasopharyngeal uptakes in Group A were confirmed to be benign. Group B showed significantly more intense FDG uptake (SUVmax of Group A 3.9 ± 1.4 vs. Group B 10.4 ± 4.6, p<0.001). and asymmetric nasopharyngeal uptake (asymmetric uptake of Group A 67.8% vs. Group B 89.6%). When SUVmax of 6.0 was used as cut off for detection of malignant nasopharyngeal uptake, the area under the ROC curve was 0.93 (95% confidence interval, 0.88-0.98), with a sensitivity of 88.1% and a specificity of 91.7%. Metastatic nodes in Group B showed higher SUVmax (Group A 2.3 ± 0.6 vs. Group B 7.1 ± 4.0, p<0.001) and larger size (short axis of Group A 5.3 ± 2.0 mm vs. Group B 13.1 ± 4.7 mm, p<0.001) than benign nodes of Group A. The majority of Group B cases demonstrated retropharyngeal lymph node uptake (70.8%), compared to only 2 cases in Group A.ConclusionsIn patients without a history of underlying malignancy involving head and neck, incidental nasopharyngeal uptake on PET/CT does not indicate malignancy. However, if the nasopharyngeal uptake is intense (SUVmax≥6.0) or concomitant retropharyngeal lymph node uptake is present, the possibility of a malignant condition should be considered.

Analysis of Cerebral Blood Flow with Single Photon Emission Computed Tomography in Mild Subcortical Ischemic Vascular Dementia

PurposeThe mechanism of cognitive dysfunction of subcortical ischemic vascular dementia (SIVaD) is not yet fully understood. The objective of this study was to investigate and compare the distribution of regional cerebral perfusion (CP) change in the mild forms of SIVaD, a relatively homogeneous subtype of vascular dementia, using statistical parametric mapping (SPM) analysis of the technetium-99m hexamethylproplyeneamineoxime (Tc-99m HMPAO) single photon emission computed tomography (SPECT).Materials and MethodsA total of 28 patients with mild SIVaD and 33 healthy controls were prospectively recruited and underwent SPECT imaging studies between January 2012 and May 2013. SPECT was performed to measure the regional CP, and SPM was applied to the analysis of the SPECT data.ResultsThe regional CP was significantly decreased in the bilateral insula, anterior and posterior cingulated gyrus, precentral gyrus, and subcallosal gyrus as well as the right inferior parietal lobule in the SIVaD patients compared to the controls (corrected p = 0.01). The pattern of CP abnormality correlated well with those previously reported in later forms of SIVaD.ConclusionsReduction of CP in the brain areas mentioned was present earlier on in the natural course of SIVaD pathophysiology. Our study suggests that cognitive dysfunction of SIVaD may be related to these regional CP deficits.

F-18 FDG PET Findings for Vogt-Koyanagi-Harada Disease

Vogt-Koyanagi-Harada disease is a rare multisystemic granulomatous autoimmune disorder affecting pigmented tissues such as the choroid, meninges, inner ear, and the skin. Neurologic symptoms are usually mild. Clinical manifestations include generalized muscle weakness, headache, meningismus, vertigo, decreased visual acuity, hearing loss and mental changes ranging from mild confusion to psychosis, hemiparesis, dysarthria, and aphasia. Seizures are very rare. We describe a case of 18F-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET) and software-fused PET-magnetic resonance imaging (MRI) in Vogt-Koyanagi-Harada disease with seizure.